menu
    • menu
    [{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Fezolinetant

    Menu

    Fezolinetant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astellas Begins Phase 3 Study of Fezolinetant for VMS in Breast Cancer Patients

                            Details : Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist being investigated for the treatment of vasomotor symptoms in patients with breast cancer.

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 27, 2024

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astellas Initiates Phase 3 Studies of Fezolinetant for Menopause-Related VMS in Japan

                            Details : Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 03, 2024

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

                            Details : Veoza (fezolinetant), an investigational oral, nonhormonal medicine in clinical development for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 13, 2023

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associat...

                            Details : Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 12, 2023

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause

                            Details : Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 28, 2023

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

                            Details : Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 13, 2023

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astellas Provides Update on Fezolinetant New Drug Application in U.S.

                            Details : ESN364 (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 20, 2023

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North ...

                            Details : Fezolinetant is an investigational selective NK3 receptor antagonist and is not approved for use anywhere in the world. Safety analyses demonstrated that both endometrial hyperplasia and endometrial malignancy were within pre-specified limits for fezolin...

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2022

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant

                            Details : Results from the SKYLIGHT 1™ and SKYLIGHT 2™ pivotal trials characterize the efficacy and safety of ESN364 (fezolinetant) for the treatment of moderate to severe VMS associated with menopause.

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 30, 2022

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant

                            Details : ESN364 (fezolinetant), an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms o...

                            Product Name : ESN364

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 18, 2022

                            Lead Product(s) : Fezolinetant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth